iShares Genomics Immunology and Healthcare ETF (IDNA)

IDNA takes a thematic bet on the intersection of two powerful trends in medicine: the falling cost of genomic sequencing and the rise of immunotherapy as a treatment approach. The fund holds companies working on DNA analysis, gene editing, immune-cell therapies, personalized medicine, and the infrastructure supporting these fields. Unlike a traditional healthcare or biotech fund, IDNA is not a broad exposure to pharmaceutical companies or medical-device makers. It is a narrowly focused play on specific cutting-edge research directions within the life sciences.

The genomics angle

Genomic sequencing — reading and interpreting a person’s genetic code — has become exponentially cheaper and faster over the past decade. What cost thousands of dollars and months of computation now costs a few hundred dollars and hours of processing. This collapse in price has opened vast new possibilities: understanding which genetic mutations drive disease, matching cancer mutations to the drugs most likely to work against them, identifying disease risk before symptoms appear, and personalizing medicine to match a patient’s genetic profile.

Companies in IDNA’s holdings operate at various points in this ecosystem. Some provide the sequencing technology itself — machines and software that read DNA. Others offer analysis platforms that interpret what the sequences mean. Still others are the drug companies and biotech firms using genetic insights to develop new treatments. A few are data companies holding large repositories of genetic information from patients or populations.

Immunotherapy and the cell-medicine revolution

The other pillar is immunotherapy — harnessing the body’s own immune system to fight disease. Rather than developing a small-molecule drug that pokes a cancer cell, an immunotherapy might train immune cells (like T cells or natural killer cells) to recognise and destroy cancer. Or it might remove immune checkpoints that allow tumours to hide. The field has expanded dramatically in the past 15 years, producing multiple FDA-approved therapies and an entirely new class of blockbuster drugs.

IDNA’s immunology holdings include companies developing therapeutic antibodies, adoptive cell therapies, checkpoint inhibitors, and related approaches. Many of these firms sit at the overlap: using genomic data to design smarter immune therapies or to predict which patients will respond to a given treatment.

Size and concentration

IDNA is a thematic ETF, which means it holds a concentrated basket focused on a defined theme rather than a broad swath of the market. With typically 30–50 holdings, it is far more concentrated than a general healthcare or biotech fund. This concentration is by design — the whole point is to track a specific story — but it also means the fund’s performance depends on whether that theme is in favour.

The holdings range from large-cap names (established pharmaceutical and biotech firms with genomics divisions) to mid-cap specialist companies to smaller pure-play genomics and immunotherapy firms. This size diversity means the fund includes both proven, profitable companies and earlier-stage, pre-revenue innovators betting on future breakthroughs.

The volatility of innovation exposure

Genomics and immunotherapy are fast-moving fields with clinical trial results that can make or break a company’s prospects. A positive trial outcome or FDA approval can send a holding soaring; a failed trial or regulatory setback can cut a share price in half. IDNA’s returns are therefore volatile, especially relative to a broad healthcare index. The fund works best for investors with a long time horizon and the temperament to sit through large drawdowns.

Beyond single-stock risk, there is also the risk of theme rotation. If investors lose enthusiasm for genomics or immunotherapy (or if another biotech theme becomes hotter), money can flow out of the fund regardless of fundamental progress. Equally, a broad market selloff in biotech or healthcare can drag IDNA down even if the underlying science is advancing.

Geographic and currency exposure

Most IDNA holdings are US and European firms, with some Asian representation. The fund is unhedged, meaning currency fluctuations against the dollar will move returns. A strong dollar can reduce the value of European holdings; a weak dollar can boost them. For a long-term investor, this is typically noise, but it is worth acknowledging.

Who IDNA is for, and what to watch

IDNA suits investors bullish on the long-term potential of genomic medicine and immunotherapy, with a time horizon of at least 5–10 years and tolerance for volatility. It is a way to take a thematic bet without having to cherry-pick individual biotech stocks. It is less suitable for conservative investors needing stable returns or those uncomfortable with the execution risk inherent in biotech.

To research IDNA, start with the fund’s prospectus and factsheet, which list the current holdings and the screening criteria for inclusion. Tracking major biotech and genomics conferences (like the American Association for Cancer Research, Genome sequencing expos, and Biotech conferences) reveals which research directions the holdings are pursuing. Following FDA clinical-trial databases and press releases shows whether key programs are progressing. News about gene therapies, CAR-T approvals, and precision-medicine breakthroughs indicate whether the theme is advancing or stalling.